Clinical trial
A Pilot, Randomized, Open-label, Single Dose Study to Evaluate the Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues on the Hepatitis B Surface Antigen of Virally Suppressed Subjects With Chronic Hepatitis B(a Multicenter, Open-labelled, Randomized Controlled Trial)
NCT05256823 is registered in ClinicalTrials.gov with Lai Wei as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot, Randomized, Open-label, Single Dose Study to Evaluate the Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues on the Hepatitis B Surface Antigen of Virally Suppressed Subjects With Chronic Hepatitis B(a Multicenter, Open-labelled, Randomized Controlled Trial)
- Lead sponsor
- Lai Wei
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- February 24, 2022
- Completion date
- December 31, 2023
- Enrollment
- 47 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
to evaluate the safety and efficacy of celecoxib plus nucleos(t)ide analogues in nucleos(t)ide-treated patients with chronic hepatitis b